{"contentid": 488103, "importid": NaN, "name": "Strong data clear path for new COVID-19 vaccine in USA", "introduction": "A long-awaited USA-based Phase III trial of Covid-19 Vaccine AstraZeneca has proved successful, paving the way for its use in the country.", "content": "<p>A long-awaited USA-based Phase III trial of Covid-19 Vaccine AstraZeneca has proved successful, paving the way for its use in the country.</p>\n<p>In the study, AstraZeneca&rsquo;s (LSE: AZN) coronavirus vaccine was 79% effective at preventing symptomatic disease and 100% effective at preventing severe disease and hospitalization.</p>\n<p>Importantly, results from the large trial show vaccine efficacy was consistent across different ethnic and age groups, with 80% effectiveness in the over-65s.</p>\n<p>The vaccine has already been approved and is in use in multiple countries, including the UK and in Europe.</p>\n<h2>European confusion</h2>\n<p>While real-world evidence has shown the vaccine&rsquo;s efficacy in older people, there has until now been a lack of clinical data from large trials confirming efficacy for this at-risk group.</p>\n<p>This had led some European regulators to advise against its use in older people, with French President Emmanuel Macron even stating it was likely &ldquo;quasi-ineffective on people older than 65.&rdquo;</p>\n<p>Commentators have now questioned whether the approach of European countries could have dented public confidence in the vaccine.</p>\n<p>The positive outcome from the American trial should help counter that effect, adding to subsequent affirmations of safety and efficacy from the European Medicines Agency and others.</p>\n<p>This was deemed necessary after several European countries paused their use of the product in order to investigate reports of blood clotting events.</p>\n<p>These suspensions came despite safety data from more than 17 million people vaccinated in the EU and the UK showing no evidence of an increased risk of pulmonary embolism, deep vein thrombosis (DVT) or thrombocytopenia.</p>\n<p>In the USA-based trial, independent data safety monitors conducted a specific review of thrombotic events and found no increased risk of thrombosis or similar events in those who received the vaccine.</p>\n<p>Executive vice president of R&amp;D for biopharma, Mene Pangalos, said: &ldquo;These results add to the growing body of evidence that shows this vaccine is well tolerated and highly effective against all severities of COVID-19 and across all age groups.&rdquo;</p>\n<p>He added: &ldquo;We are preparing to submit these findings to the US Food and Drug Administration and for the rollout of millions of doses across America should the vaccine be granted US Emergency Use Authorization.&rdquo;</p>", "date": "2021-03-22 10:17:00", "meta_title": NaN, "meta_keywords": "vaccine, trial, data, European, efficacy, USA-based, people, Strong, path, clear, Phase, COVID-, Covid-, AstraZeneca, proved, successful, paving, country", "meta_description": "A long-awaited USA-based Phase III trial of Covid-19 Vaccine AstraZeneca has proved successful, paving the way for its use in the country.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-22 10:16:48", "updated": "2021-03-22 10:36:14", "access": NaN, "url": "https://www.thepharmaletter.com/article/strong-data-clear-path-for-new-covid-19-vaccine-in-usa", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "astrazeneca_big.jpg", "image2id": "astrazeneca_small-1.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Infectious diseases, Vaccines", "topic_tag": "Coronavirus, Drug Trial, Focus On, Research", "geography_tag": "UK, USA", "company_tag": "AstraZeneca", "drug_tag": "COVID-19 Vaccine AstraZeneca", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-22 10:17:00"}